Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02233257|
Expanded Access Status : No longer available
First Posted : September 8, 2014
Last Update Posted : January 23, 2018
X-linked adrenoleukodystrophy (ALD) is a genetic disorder affecting the brain and adrenal glands. Approximately one third of boys who are at risk will develop cerebral disease. Using a specific diet and the compound Lorenzo's oil, it can be shown that very long chain fatty acids may be lowered in the blood, but it is not known to what degree that may prevent the onset of childhood disease.
This proposal makes available Lorenzo's oil to individuals with ALD, a life threatening disorder for which there are presently no other therapies.
|Condition or disease||Intervention/treatment|
|X-linked Adrenoleukodystrophy||Drug: Lorenzo's Oil|
|Study Type :||Expanded Access|
|Official Title:||Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy|
- Drug: Lorenzo's Oil
Oral use of Lorenzo's oil to lower very long chain fatty acidsOther Name: Glyceryl trierucate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02233257
|United States, Minnesota|
|University of Minnesota Medical Center|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Gerald V Raymond, MD||University of Minnesota|